varegacestat
Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo
Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
Immunome; Q3 2025; financial results; business update; pipeline update; cancer therapies; RINGSIDE trial; varegacestat; IM-1021; B-cell lymphoma; clinical trials; ADC; net loss; cash position